Mitochondrial and Cellular Biomarkers of Renal Injury from Environmental and Therapeutic Agents

环境和治疗药物引起的肾损伤的线粒体和细胞生物标志物

基本信息

  • 批准号:
    10388109
  • 负责人:
  • 金额:
    $ 36.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-09 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

Abstract: Exposure to a broad range of environmental contaminants, including halogenated solvents, polycyclic aromatic hydrocarbons, and heavy metals, can cause kidney injury. Acute kidney injury (AKI) is also a dose-limiting side effect of several classes of therapeutic drugs, including many antibiotics, antiviral agents, anticancer chemotherapeutic agents, and NSAIDs. Although some highly sensitive protein biomarkers have been validated in recent years, they are still associated with some degree of renal damage. Markers that can indicate exposure yet be detected prior to any or after only minimal injury are preferable. Additionally, identification of new markers that are more closely linked to mechanism of action will enhance understanding of mechanism and improve therapeutics. Our approach to identification of such mechanistic markers has focused primarily on the mitochondria as common, early, and sensitive targets in proximal tubular cells for an array of environmental contaminants and therapeutic drugs. We will use primary cultures of proximal tubular cells from human kidneys (hPT cells) as the experimental model system. Our overall hypothesis is that exposure of hPT cells to environmentally or therapeutically relevant concentrations of toxicants or therapeutic agents, respectively, will modify mitochondria and other cellular components and result in release of selected proteins and lipids and altered patterns of metabolites. Although association of mitochondrial dysfunction with various forms of kidney injury and disease is well-established, our application of this central, underlying concept to identify mechanistically-based biomarkers is novel. hPT cells will be treated with two environmental contaminants (the trichloroethylene metabolite S-(1,2-dichlorovinyl)-L-cysteine [DCVC] and HgCl2) or three therapeutic agents (tenofovir disoproxil fumarate, cisplatin, and polymyxin B) that all target renal mitochondria. Additionally, antimycin A will be used as a positive control. Preliminary studies helped refine the hypothesis and identified three specific proteins, one mitochondrial (sulfite oxidase), one cytoskeletal (keratins), and one cytoplasmic (HSP90), as potential biomarkers and take a targeted approach for validation. Specific Aim 1 will take a targeted approach to determine the utility of released proteins from hPT cells as biomarkers. We will test whether release of mitochondrial sulfite oxidase, cytoskeletal keratins, and cytoplasmic HSP90 reflect exposure to and proximal tubular toxicity from nephrotoxicants. Release of proteins will be correlated with parameters of renal cell function and viability and other well-established biomarkers. Specific Aim 2 will focus on modified (adducted or oxidized) proteins in hPT cells as biomarkers. Specific Aim 3 will focus on release of cardiolipins, other lipids, and intermediary metabolites as sensitive indicators of exposure to and proximal tubular toxicity from nephrotoxicants. Finally, Specific Aim 4 will focus on the potential identification of proteins in exposomes, including those identified in Aims 1 and 2, as another potential source of sensitive markers of exposure and injury.
摘要: 暴露于各种环境污染物,包括卤化溶剂、多环芳烃 碳氢化合物和重金属会导致肾损伤。急性肾损伤(阿基)也是一个剂量限制性方面 几类治疗药物的作用,包括许多抗生素,抗病毒剂,抗癌药, 化疗剂和NSAID。尽管一些高度敏感的蛋白质生物标志物已经被 尽管近年来得到证实,但它们仍与一定程度的肾损伤有关。标记可以 优选在任何损伤之前或仅在最小损伤之后检测到指示暴露。此外,本发明还 确定与作用机制更密切相关的新标志物将增进了解, 机制和改善治疗方法。我们鉴定这种机械标记物的方法 主要集中在线粒体作为常见的,早期的,和敏感的目标,在近端肾小管细胞, 一系列环境污染物和治疗药物。我们将使用原代培养的近端肾小管 来自人肾的细胞(hPT细胞)作为实验模型系统。我们的总体假设是 将hPT细胞暴露于环境或治疗相关浓度的毒物或治疗剂 试剂将分别修饰线粒体和其他细胞组分,并导致释放选定的 蛋白质和脂质以及改变的代谢物模式。虽然线粒体功能障碍与 各种形式的肾损伤和疾病是公认的,我们的应用这一中心,基础 识别基于机械的生物标志物的概念是新颖的。hPT细胞将用两种环境 污染物(三氯乙烯代谢产物S-(1,2-二氯乙烯基)-L-半胱氨酸[DCVC]和HgCl 2)或三种 治疗剂(富马酸替诺福韦酯、顺铂和多粘菌素B)均靶向肾线粒体。 此外,抗霉素A将用作阳性对照。初步研究有助于完善这一假设 并确定了三种特异性蛋白质,一种是线粒体蛋白(亚硫酸氧化酶),一种是细胞骨架蛋白(角蛋白), 细胞质(HSP 90),作为潜在的生物标志物,并采取有针对性的方法进行验证。具体目标1将 采取靶向方法来确定从hPT细胞释放的蛋白质作为生物标志物的效用。我们将测试 线粒体亚硫酸盐氧化酶、细胞骨架角蛋白和细胞质HSP 90的释放是否反映了 暴露于肾毒物和近端肾小管毒性。蛋白质的释放将与 肾细胞功能和存活力的参数以及其他公认的生物标志物。第2章重点 作为生物标志物的hPT细胞中修饰的(加合或氧化的)蛋白质。具体目标3将集中在释放 心磷脂、其他脂质和中间代谢物作为暴露和近端 肾毒物的肾小管毒性。最后,具体目标4将侧重于蛋白质的潜在鉴定 在染色体中,包括在目的1和2中鉴定的那些,作为敏感的标记物的另一个潜在来源, 暴露和伤害。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LAWRENCE H. LASH其他文献

LAWRENCE H. LASH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LAWRENCE H. LASH', 18)}}的其他基金

Mitochondrial and Cellular Biomarkers of Renal Injury from Environmental and Therapeutic Agents
环境和治疗药物引起的肾损伤的线粒体和细胞生物标志物
  • 批准号:
    10559604
  • 财政年份:
    2021
  • 资助金额:
    $ 36.9万
  • 项目类别:
Molecular Toxicology in Human Kidney Cells
人肾细胞的分子毒理学
  • 批准号:
    7216674
  • 财政年份:
    1999
  • 资助金额:
    $ 36.9万
  • 项目类别:
Molecular Toxicology in Human Kidney Cells
人肾细胞的分子毒理学
  • 批准号:
    6781240
  • 财政年份:
    1999
  • 资助金额:
    $ 36.9万
  • 项目类别:
Molecular Toxicology in Human Kidney Cells
人肾细胞的分子毒理学
  • 批准号:
    7009799
  • 财政年份:
    1999
  • 资助金额:
    $ 36.9万
  • 项目类别:
MOLECULAR TOXICOLOGY IN HUMAN KIDNEY CELLS
人肾细胞的分子毒理学
  • 批准号:
    2908529
  • 财政年份:
    1999
  • 资助金额:
    $ 36.9万
  • 项目类别:
MOLECULAR TOXICOLOGY IN HUMAN KIDNEY CELLS
人肾细胞的分子毒理学
  • 批准号:
    6178509
  • 财政年份:
    1999
  • 资助金额:
    $ 36.9万
  • 项目类别:
Molecular Toxicology in Human Kidney Cells
人肾细胞的分子毒理学
  • 批准号:
    6889180
  • 财政年份:
    1999
  • 资助金额:
    $ 36.9万
  • 项目类别:
Molecular Toxicology in Human Kidney Cells
人肾细胞的分子毒理学
  • 批准号:
    7046832
  • 财政年份:
    1999
  • 资助金额:
    $ 36.9万
  • 项目类别:
MOLECULAR TOXICOLOGY IN HUMAN KIDNEY CELLS
人肾细胞的分子毒理学
  • 批准号:
    6382219
  • 财政年份:
    1999
  • 资助金额:
    $ 36.9万
  • 项目类别:
CHRONIC AND ACUTE CYTOTOXICITY IN KIDNEY CELLS
肾细胞的慢性和急性细胞毒性
  • 批准号:
    2133781
  • 财政年份:
    1993
  • 资助金额:
    $ 36.9万
  • 项目类别:

相似海外基金

Can antibiotics disrupt biogeochemical nitrogen cycling in the coastal ocean?
抗生素会破坏沿海海洋的生物地球化学氮循环吗?
  • 批准号:
    2902098
  • 财政年份:
    2024
  • 资助金额:
    $ 36.9万
  • 项目类别:
    Studentship
The role of RNA repair in bacterial responses to translation-inhibiting antibiotics
RNA修复在细菌对翻译抑制抗生素的反应中的作用
  • 批准号:
    BB/Y004035/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.9万
  • 项目类别:
    Research Grant
Metallo-Peptides: Arming Cyclic Peptide Antibiotics with New Weapons to Combat Antimicrobial Resistance
金属肽:用新武器武装环肽抗生素以对抗抗菌素耐药性
  • 批准号:
    EP/Z533026/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.9万
  • 项目类别:
    Research Grant
Towards the sustainable discovery and development of new antibiotics
迈向新抗生素的可持续发现和开发
  • 批准号:
    FT230100468
  • 财政年份:
    2024
  • 资助金额:
    $ 36.9万
  • 项目类别:
    ARC Future Fellowships
DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
  • 批准号:
    EP/Y023528/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.9万
  • 项目类别:
    Research Grant
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
  • 批准号:
    BB/Y007611/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.9万
  • 项目类别:
    Research Grant
The disulfide bond as a chemical tool in cyclic peptide antibiotics: engineering disulfide polymyxins and murepavadin
二硫键作为环肽抗生素的化学工具:工程化二硫多粘菌素和 murepavadin
  • 批准号:
    MR/Y033809/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.9万
  • 项目类别:
    Research Grant
Role of phenotypic heterogeneity in mycobacterial persistence to antibiotics: Prospects for more effective treatment regimens
表型异质性在分枝杆菌对抗生素持久性中的作用:更有效治疗方案的前景
  • 批准号:
    494853
  • 财政年份:
    2023
  • 资助金额:
    $ 36.9万
  • 项目类别:
    Operating Grants
Imbalance between cell biomass production and envelope biosynthesis underpins the bactericidal activity of cell wall -targeting antibiotics
细胞生物量产生和包膜生物合成之间的不平衡是细胞壁靶向抗生素杀菌活性的基础
  • 批准号:
    2884862
  • 财政年份:
    2023
  • 资助金额:
    $ 36.9万
  • 项目类别:
    Studentship
Narrow spectrum antibiotics for the prevention and treatment of soft-rot plant disease
防治植物软腐病的窄谱抗生素
  • 批准号:
    2904356
  • 财政年份:
    2023
  • 资助金额:
    $ 36.9万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了